Nurix and Roche Forge Strategic Collaboration for Bexobrutideg Development
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Newsfilter
- Strategic Collaboration: Nurix has entered a global partnership with Roche to develop the oral BTK degrader bexobrutideg, receiving an upfront payment of $700 million and potential milestone payments up to $2.3 billion, reflecting strong confidence in the drug's development prospects.
- Clinical Development Plan: The collaboration will cover malignant hematology, immunology, and neurology, with plans for Phase 2 and Phase 3 trials in multiple indications, including chronic lymphocytic leukemia (CLL), aimed at fully exploring the clinical potential of BTK degradation.
- Profit-Sharing Mechanism: In the U.S. market, Nurix and Roche will share development costs (40% Nurix, 60% Roche) and split profits and losses equally, enhancing Nurix's competitive position in the market through this collaborative model.
- Innovative Drug Advantages: Bexobrutideg, as a novel BTK degrader, offers high selectivity and oral administration benefits, effectively addressing resistance issues associated with existing BTK inhibitors, and is expected to provide more durable treatment outcomes for patients with B-cell malignancies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NRIX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NRIX
Wall Street analysts forecast NRIX stock price to rise
13 Analyst Rating
13 Buy
0 Hold
0 Sell
Strong Buy
Current: 15.280
Low
22.00
Averages
31.08
High
41.00
Current: 15.280
Low
22.00
Averages
31.08
High
41.00
About NRIX
Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, aimed at improving treatment options for patients with cancer and autoimmune diseases. The Company's wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. The Company's portfolio of targeted protein degraders of the B‑cell signaling protein BTK comprises bexobrutideg (NX‑5948) and zelebrudomide (NX‑2127). The Company's degradation inhibitor program includes NX-1607, an orally bioavailable inhibitor of CBL-B, an E3 ligase that regulates the activation of multiple immune cell types including T cells and NK cells. NX-1607 is targeted for immuno-oncology indications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nurix and Roche Forge Strategic Collaboration for Bexobrutideg Development
- Strategic Collaboration: Nurix has entered a global partnership with Roche to develop the oral BTK degrader bexobrutideg, receiving an upfront payment of $700 million and potential milestone payments up to $2.3 billion, reflecting strong confidence in the drug's development prospects.
- Clinical Development Plan: The collaboration will cover malignant hematology, immunology, and neurology, with plans for Phase 2 and Phase 3 trials in multiple indications, including chronic lymphocytic leukemia (CLL), aimed at fully exploring the clinical potential of BTK degradation.
- Profit-Sharing Mechanism: In the U.S. market, Nurix and Roche will share development costs (40% Nurix, 60% Roche) and split profits and losses equally, enhancing Nurix's competitive position in the market through this collaborative model.
- Innovative Drug Advantages: Bexobrutideg, as a novel BTK degrader, offers high selectivity and oral administration benefits, effectively addressing resistance issues associated with existing BTK inhibitors, and is expected to provide more durable treatment outcomes for patients with B-cell malignancies.
See More
Nurix Therapeutics Executive Stock Sale Amid Strong Gains
- Executive Stock Sale: Christine Ring, Chief Legal Officer of Nurix Therapeutics, sold 5,394 shares for approximately $90,000 on May 1, 2026, reflecting a strategic reduction in her holdings amid the company's strong stock performance.
- Equity Exposure Change: Following the sale, Ring retains 26,453 shares, representing about 0.03% of the company's outstanding shares, indicating her continued confidence in the company's future despite a decrease in her ownership percentage.
- Transaction Size Analysis: Ring's recent activity includes four direct sales averaging around 8,987 shares each over the past year, with the May 1 sale being on the lower end, suggesting a reduction in available shares rather than a shift in strategy.
- Company Financial Status: Nurix Therapeutics reported an $87.2 million loss in its fiscal first quarter of 2026, yet its candidate drug bexobrutideg for chronic lymphocytic leukemia could lead to significant financial improvements if successful in upcoming clinical trials.
See More
Nurix Therapeutics Reports Q1 Loss and Revenue Decline
- Widening Net Loss: Nurix Therapeutics reported a net loss of $87.2 million for Q1, translating to a loss of $0.79 per share, which is a significant increase from last year's loss of $56.4 million or $0.67 per share, indicating a deterioration in the company's financial health.
- Significant Revenue Decline: The company's revenue for the first quarter was $6.3 million, a sharp drop from $18.5 million a year ago, primarily due to decreased revenue from its collaboration with Sanofi, reflecting the direct impact of the conclusion of the initial research phase on income.
- Stable Cash Reserves: As of February 28, 2026, Nurix held $540.7 million in cash, cash equivalents, and marketable securities, indicating that despite the losses, the company maintains a relatively strong liquidity position to support future R&D activities.
- Stock Price Volatility: In pre-market trading on Nasdaq, Nurix shares fell by 3.06% to $15.85, reflecting a negative investor reaction to the earnings report, which could impact the company's future financing capabilities and market confidence.
See More
Nurix Therapeutics Q1 Earnings Miss Expectations
- Disappointing Earnings: Nurix Therapeutics reported a Q1 GAAP EPS of -$0.79, missing expectations by $0.02, indicating ongoing pressure on profitability that could undermine investor confidence.
- Significant Revenue Decline: The company generated $6.25M in revenue, a 66.1% year-over-year decrease, falling short of the anticipated $7.99M, reflecting a notable weakness in product sales and market demand that may lead to tighter cash flow in the future.
- Decreased Cash Reserves: As of February 28, 2026, cash, cash equivalents, and marketable securities stood at $540.7M, down from $592.9M on November 30, 2025, highlighting challenges in financial management that could impact R&D and operational capabilities.
- Uncertain Market Outlook: Although the company showcased potential growth opportunities at the J.P. Morgan Healthcare Conference, the current financial performance and market reactions may limit future investment appeal, necessitating cautious risk assessment by investors.
See More
Nurix Advances Bexobrutideg Trials for CLL Treatment
- Clinical Trial Progress: Nurix's ongoing DAYBreak CLL-201 Phase 2 trial aims to support Accelerated Approval for relapsed/refractory chronic lymphocytic leukemia (r/r CLL), currently enrolling patients to address significant unmet medical needs in this area.
- Future Plans: Nurix plans to initiate the DAYBreak CLL-306 Phase 3 global randomized confirmatory trial by mid-2026, comparing the efficacy of bexobrutideg against the recently approved non-covalent inhibitor pirtobrutinib, further advancing its application in r/r CLL.
- Financial Position: As of February 28, 2026, Nurix reported $540.7 million in cash and cash equivalents, although revenue decreased from $18.5 million in 2025 to $6.3 million, indicating ongoing investment in R&D despite financial challenges.
- Increased R&D Spending: The R&D expenses for Q1 2026 reached $84.1 million, up from $69.7 million in Q1 2025, primarily driven by accelerated patient enrollment for bexobrutideg and preparations for Phase 3 trials, reflecting the company's commitment to its product pipeline.
See More
NURIX THERAPEUTICS ANNOUNCES FINANCIAL RESULTS FOR FIRST QUARTER 2026 AND SHARES COMPANY UPDATE
Financial Results: NURIX Therapeutics reported its financial results for the first quarter of 2026, detailing revenue and expenses.
Corporate Update: The report includes a corporate update, highlighting recent developments and strategic initiatives within the company.
See More
Nurix and Roche Forge Strategic Collaboration for Bexobrutideg Development
- Strategic Collaboration: Nurix has entered a global partnership with Roche to develop the oral BTK degrader bexobrutideg, receiving an upfront payment of $700 million and potential milestone payments up to $2.3 billion, reflecting strong confidence in the drug's development prospects.
- Clinical Development Plan: The collaboration will cover malignant hematology, immunology, and neurology, with plans for Phase 2 and Phase 3 trials in multiple indications, including chronic lymphocytic leukemia (CLL), aimed at fully exploring the clinical potential of BTK degradation.
- Profit-Sharing Mechanism: In the U.S. market, Nurix and Roche will share development costs (40% Nurix, 60% Roche) and split profits and losses equally, enhancing Nurix's competitive position in the market through this collaborative model.
- Innovative Drug Advantages: Bexobrutideg, as a novel BTK degrader, offers high selectivity and oral administration benefits, effectively addressing resistance issues associated with existing BTK inhibitors, and is expected to provide more durable treatment outcomes for patients with B-cell malignancies.
See More
Nurix Therapeutics Executive Stock Sale Amid Strong Gains
- Executive Stock Sale: Christine Ring, Chief Legal Officer of Nurix Therapeutics, sold 5,394 shares for approximately $90,000 on May 1, 2026, reflecting a strategic reduction in her holdings amid the company's strong stock performance.
- Equity Exposure Change: Following the sale, Ring retains 26,453 shares, representing about 0.03% of the company's outstanding shares, indicating her continued confidence in the company's future despite a decrease in her ownership percentage.
- Transaction Size Analysis: Ring's recent activity includes four direct sales averaging around 8,987 shares each over the past year, with the May 1 sale being on the lower end, suggesting a reduction in available shares rather than a shift in strategy.
- Company Financial Status: Nurix Therapeutics reported an $87.2 million loss in its fiscal first quarter of 2026, yet its candidate drug bexobrutideg for chronic lymphocytic leukemia could lead to significant financial improvements if successful in upcoming clinical trials.
See More
Nurix Therapeutics Reports Q1 Loss and Revenue Decline
- Widening Net Loss: Nurix Therapeutics reported a net loss of $87.2 million for Q1, translating to a loss of $0.79 per share, which is a significant increase from last year's loss of $56.4 million or $0.67 per share, indicating a deterioration in the company's financial health.
- Significant Revenue Decline: The company's revenue for the first quarter was $6.3 million, a sharp drop from $18.5 million a year ago, primarily due to decreased revenue from its collaboration with Sanofi, reflecting the direct impact of the conclusion of the initial research phase on income.
- Stable Cash Reserves: As of February 28, 2026, Nurix held $540.7 million in cash, cash equivalents, and marketable securities, indicating that despite the losses, the company maintains a relatively strong liquidity position to support future R&D activities.
- Stock Price Volatility: In pre-market trading on Nasdaq, Nurix shares fell by 3.06% to $15.85, reflecting a negative investor reaction to the earnings report, which could impact the company's future financing capabilities and market confidence.
See More
Nurix Therapeutics Q1 Earnings Miss Expectations
- Disappointing Earnings: Nurix Therapeutics reported a Q1 GAAP EPS of -$0.79, missing expectations by $0.02, indicating ongoing pressure on profitability that could undermine investor confidence.
- Significant Revenue Decline: The company generated $6.25M in revenue, a 66.1% year-over-year decrease, falling short of the anticipated $7.99M, reflecting a notable weakness in product sales and market demand that may lead to tighter cash flow in the future.
- Decreased Cash Reserves: As of February 28, 2026, cash, cash equivalents, and marketable securities stood at $540.7M, down from $592.9M on November 30, 2025, highlighting challenges in financial management that could impact R&D and operational capabilities.
- Uncertain Market Outlook: Although the company showcased potential growth opportunities at the J.P. Morgan Healthcare Conference, the current financial performance and market reactions may limit future investment appeal, necessitating cautious risk assessment by investors.
See More
Nurix Advances Bexobrutideg Trials for CLL Treatment
- Clinical Trial Progress: Nurix's ongoing DAYBreak CLL-201 Phase 2 trial aims to support Accelerated Approval for relapsed/refractory chronic lymphocytic leukemia (r/r CLL), currently enrolling patients to address significant unmet medical needs in this area.
- Future Plans: Nurix plans to initiate the DAYBreak CLL-306 Phase 3 global randomized confirmatory trial by mid-2026, comparing the efficacy of bexobrutideg against the recently approved non-covalent inhibitor pirtobrutinib, further advancing its application in r/r CLL.
- Financial Position: As of February 28, 2026, Nurix reported $540.7 million in cash and cash equivalents, although revenue decreased from $18.5 million in 2025 to $6.3 million, indicating ongoing investment in R&D despite financial challenges.
- Increased R&D Spending: The R&D expenses for Q1 2026 reached $84.1 million, up from $69.7 million in Q1 2025, primarily driven by accelerated patient enrollment for bexobrutideg and preparations for Phase 3 trials, reflecting the company's commitment to its product pipeline.
See More
NURIX THERAPEUTICS ANNOUNCES FINANCIAL RESULTS FOR FIRST QUARTER 2026 AND SHARES COMPANY UPDATE
Financial Results: NURIX Therapeutics reported its financial results for the first quarter of 2026, detailing revenue and expenses.
Corporate Update: The report includes a corporate update, highlighting recent developments and strategic initiatives within the company.
See More
